Photochemical treatment of plasma with amotosalen and long‐wavelength ultraviolet light inactivates pathogens while retaining coagulation function

Abstract

PCT of plasma inactivated high levels of a wide range of pathogens while maintaining adequate coagulation function. PCT has the potential to reduce the risk of transfusion-transmitted diseases in patients requiring plasma transfusion support.

Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice

“…Additionally, they induce the cross-linking of pyrimidines only following UV exposure (5,6). This feature of psoralens has made them attractive in transfusion medicine for pathogen inactivation (1,7,11), particularly the use of amotosalen as an alternative to traditional leukocyte reduction methods for the prevention of parvovirus (1) and cytomegalovirus (10) transmission.…”

Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light

“…Treatment of the resultant complexes with UVA illumination leads to the formation of inter-and cross-strand links between pyrimidine bases, which prevents pathogen replication and transcription. 47 In vitro studies have shown that photochemical treatment with amotosalen and UVA does not substantially affect platelet or plasma function 40,41,48,49 and clinical trials indicated that transfusion of psoralen-treated platelets or plasma to patients does not result in adverse immunologic or hemorrhagic responses. [50][51][52][53] More than a million kits to prepare IBS platelets and plasma have been sold since the introduction of the system in Europe.…”

“…Detailed haemovigilance and post marketing surveillance in Europe since 2003 continues to demonstrate safety and efficacy of the treated products. [54][55][56][57][58] Although high levels of inactivation have been demonstrated for a number of viruses including single-stranded RNA viruses, 38,40 the efficacy of amotosalen and UVA treatment of inactivation of high CHIKV doses had not been tested. Here, we describe the successful inactivation of high doses of CHIKV in apheresis platelet concentrates and plasma components using the amotosalen and UVA treatment process.…”

Humanes Immunschwächevirus (HIV)

“…Psoralen S-58 [205][206][207][208][209][210][211]. Klinische Studien zur Wirksamkeit und Verträglichkeit von Methylenblau-und SD-inaktiviertem und von Amotosalen- [208] und Riboflavin-behandeltem Plasma [211] sind nur begrenzt durchgeführt worden [212].…”

“…Klinische Studien zur Wirksamkeit und Verträglichkeit von Methylenblau-und SD-inaktiviertem und von Amotosalen- [208] und Riboflavin-behandeltem Plasma [211] sind nur begrenzt durchgeführt worden [212]. Eine weitere Substanz zur Inaktivierung von HIV in Vollblut oder Erythrozytenkonzentrat ist S-303 [213].…”